PrEP Use and Adherence among Transgender Persons in Chicago, IL (SHIPP Study, 2014

PrEP Use and Adherence among Transgender Persons in Chicago, IL (SHIPP Study, 2014–2018, USA)

Published:2022-09-12 Issue:3 Volume:27 Page:901-908
ISSN:1090-7165
Container-title:AIDS and Behavior
language:en
Short-container-title:AIDS Behav

Author:

Townes Ashley^ORCID,Pyra Maria,Smith Dawn K.,Babu Aruna Surendera,Williams Tiffany,Wiener Jeffrey,Henny Kirk D.,Schneider John

Funder

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Social Psychology

Link

https://link.springer.com/content/pdf/10.1007/s10461-022-03826-y.pdf

Reference28 articles.

1. Centers for Disease Control and Prevention. HIV and transgender people. https://www.cdc.gov/hiv/pdf/group/gender/transgender/cdc-hiv-transgender-factsheet.pdf. Published April 2021. [Accessed July 6, 2021].

2. Centers for Disease Control and Prevention. Surveillance Report HIV. 2019; vol.32. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2021. [Accessed July 6, 2021].

3. Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: A systematic review and meta-analysis, 2006–2017. AJPH. 2019;109:e1–8.

4. Centers for Disease Control and Prevention. US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018. [Accessed July 6, 2021].

5. Escudero DJ, Kerr T, Operario D, Socias ME, Sued O, Marshall BD. Inclusion of trans women in pre-exposure prophylaxis trials: a review. AIDS Care. 2015;27(5):637–41.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No observed bidirectional effect between tenofovir diphosphate concentrations and gender‐affirming hormone concentrations among transgender persons switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre‐exposure prophylaxis;British Journal of Clinical Pharmacology;2024-04-22

2. Bacterial vaginosis testing gaps for transmasculine patients may exacerbate health disparities;Frontiers in Reproductive Health;2024-02-20

3. Characteristics Associated with Pre-Exposure Prophylaxis Discussion and Use Among Transgender Women Without HIV Infection — National HIV Behavioral Surveillance Among Transgender Women, Seven Urban Areas, United States, 2019–2020;MMWR Supplements;2024-01-25